- Home
- FGB vs MGX Comparison
FGB vs MGX Comparison
Compare FGB & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- MGX
- Stock Information
- Founded
- FGB 2007
- MGX 2018
- Country
- FGB United States
- MGX United States
- Employees
- FGB N/A
- MGX N/A
- Industry
- FGB Finance/Investors Services
- MGX
- Sector
- FGB Finance
- MGX
- Exchange
- FGB Nasdaq
- MGX NYSE
- Market Cap
- FGB 60.1M
- MGX 58.7M
- IPO Year
- FGB N/A
- MGX 2024
- Fundamental
- Price
- FGB $3.85
- MGX $1.52
- Analyst Decision
- FGB
- MGX Strong Buy
- Analyst Count
- FGB 0
- MGX 5
- Target Price
- FGB N/A
- MGX $13.00
- AVG Volume (30 Days)
- FGB 53.0K
- MGX 434.7K
- Earning Date
- FGB 01-01-0001
- MGX 05-13-2025
- Dividend Yield
- FGB 8.92%
- MGX N/A
- EPS Growth
- FGB N/A
- MGX N/A
- EPS
- FGB N/A
- MGX N/A
- Revenue
- FGB N/A
- MGX $52,295,000.00
- Revenue This Year
- FGB N/A
- MGX N/A
- Revenue Next Year
- FGB N/A
- MGX $6.95
- P/E Ratio
- FGB N/A
- MGX N/A
- Revenue Growth
- FGB N/A
- MGX 16.84
- 52 Week Low
- FGB $2.85
- MGX $1.23
- 52 Week High
- FGB $3.74
- MGX $8.42
- Technical
- Relative Strength Index (RSI)
- FGB 40.41
- MGX 44.88
- Support Level
- FGB $3.61
- MGX $1.42
- Resistance Level
- FGB $3.83
- MGX $1.55
- Average True Range (ATR)
- FGB 0.16
- MGX 0.13
- MACD
- FGB -0.01
- MGX 0.05
- Stochastic Oscillator
- FGB 48.42
- MGX 78.38
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.